<DOC>
	<DOCNO>NCT00526838</DOCNO>
	<brief_summary>The purpose study assess safety tolerability multi-targeted protein kinase inhibitor XL228 ( active IGF1R , Src , FGFR , BCR-Abl ) administer once- twice-weekly 1-hour intravenous infusion subject advanced malignancy .</brief_summary>
	<brief_title>Study XL228 Administered Intravenously Subjects With Advanced Malignancies</brief_title>
	<detailed_description />
	<criteria>The subject histologically confirm solid tumor metastatic unresectable , lymphoma , multiple myeloma , standard curative palliative measure exist longer effective , know therapy prolong survival . Subjects treat MTD ( onceweekly ) must diagnosis metastice colorectal carcinoma , relapse refractory multiple myeloma , nonsmallcell lung cancer ( NSCLC ) , small cell lung cancer ( SCLC ) . Certain eligibility requirement must also meet . The subject disease assessable tumor marker , clinical laboratory , physical , radiologic mean . The subject ≥18 year old . The subject Eastern Cooperative Oncology Group ( ECOG ) performance status ≤2 . The subject adequate organ marrow function . The subject capable understanding inform consent document sign informed consent document . Sexually active subject ( male female ) must use medically acceptable method contraception course study . Female subject childbearing potential must negative serum pregnancy test screening . The subject receive anticancer treatment ( eg , chemotherapy , radiotherapy , cytokine , investigational agent , hormone ) within 14 day first dose study drug . The subject receive radiation &gt; 25 % bone marrow within 30 day treatment XL228 . The subject recover National Cancer Institute ( NCI ) Common Terminology Criteria Adverse Events ( CTCAE ) v3.0 Grade ≤1 adverse event ( AEs ) due investigational agent administer 14 day prior study enrollment . The subject primary brain tumor . Subjects brain metastasis consider eligible subject receive radiation therapy brain metastasis within 2 week enrollment stable dose steroid 2 week . The subject uncontrolled intercurrent illness include , limited , ongoing active infection , diabetes , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia . The subject psychiatric illness social situation would limit compliance study requirement . The subject pregnant breastfeeding . The subject know positive human immunodeficiency virus ( HIV ) . The subject know allergy hypersensitivity component XL228 formulation . The subject unable unwilling abide study protocol cooperate fully investigator designee .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Solid Tumor</keyword>
	<keyword>Multiple Myeloma</keyword>
</DOC>